Share 'PPMD Submits Community Sign-On Letter to FDA Supporting Approval of Ataluren'
PPMD has been continuing to engage with both PTC and the FDA on behalf of the patient community regarding the regulatory review of ataluren.
Earlier this month, PPMD reached out to FDA requesting guidance on the best mechanism for patient input during the formal dispute process with PTC. We have learned that there is no formal process to submit such information.
We understand that the formal…
You can share this blog post in two ways…
Share this link:
Send it with your computer's email program: Email this